About IXICO

We are working to advance therapies for neurological diseases by transforming data into clinically meaningful insights.

Our exceptional team brings together world-class therapeutic expertise, breakthrough analytics and operational excellence – making us the partner of choice for imaging biomarker solutions in CNS clinical trials.

Supporting entire drug development lifecycle

We help you make better-informed decisions earlier in the drug development journey. The analytics and insight we provide enable you to accelerate R&D decision making, de-risk clinical research, and maximize the value of sponsors’ drug development pipelines.

Our neuroimaging and digital biomarker solutions power some of the most important clinical trials in neuroscience today. Our advanced imaging technologies unlock valuable insights into drug safety and efficacy across the entire drug development lifecycle, from Phase I, to commercialization, to post-marketing.

Our specialist data analytics services identify and measure unique biomarkers from brain scans and wearable biosensors. The insight we deliver supports your clinical decision-making from patient selection and safety to disease progression and drug efficacy.  

To find out more, download our latest brochure

IXICO's timeline

Top timeline logo

2004

IXICO founded

A spin-out from London universities' ‘Information eXtraction from Images’ project.

2006

Clinical trial platform launched

IXICO provides neuroscience expertise and global operations to deliver imaging and digital biomarker analytical services for clinical development, within a framework of regulatory compliance.

2007

First Phase 3 trial

IXICO is awarded it's first Phase 3 study for Alzheimer's disease.

2008

Web-based TrialTracker platform launched

The TrialTrackerTM data managment platform is a secure and compliant environment for the collection, analysis and interpretation of large image files and other data that may be generated in the course of a clinical study.

2013

AIM listing

IXICO was listed on the Alternative Investment Market (AIM), a sub-market of the London Stock Exchange (LSE).

2014

Assessa platform launched

The clinical decision support platform, Assessa provides access to expert neuroradiologists for a standardized radiological read, and securely captures then transfers clinical data and MR images from referring neurologists to expert neuroradiologists.

2015

Post-marketing surveillance commercial collaboration

IXICO are partnering with pharma companies to develop digital clinical decision support technologies based on our Assessa platform technology to improve the targeting and the safety and effectiveness of their therapeutics.

2017

Digital biomarkers commercial collaboration

The arrival of connected digital technologies (wearable biosensors and mobile devices) that enable the passive measurement of parameters such as sleep, activity and heart rate outside of the clinic, has provided the opportunity to revolutionize the capture of data in clinical trials.

READ MORE about Innovation at IXICO

2018

Product Investment

Oversubscribed placing of £5.5m to invest in new product and new market development

2019

King's College Partnership

IXICO was chosen as partner for King's College London's UK Government-funded Medical Imaging & Artificial Intelligence Centre

Public & Private Partnerships

Collaboration within clinical research is key to advancing treatments for neurological diseases. Working with partners in academia, business and charitable organisations, we help further the international scientific and regulatory agenda. We provide access to our platform and advanced data analysis for more accurate and applicable insights that further neurological research. We are also working with partners to develop new analytical techniques and digital health products to improve patient outcomes.

 

Read more

Work with us

Careers at IXICO

We are a passionate, dedicated, fast-growing team of scientists, researchers, quality professionals, and business people specializing in supporting clinical research in neuroscience – in particular neurodegenerative diseases. We work with biopharmaceutical clients, academic partners and clinical research sites around the world, innovating, developing and delivering cutting-edge technologies to support our clients' evolving clinical research needs.

View our vacancies